Slide 1: Pfizer Pflash: A Spotlight on Pfizer's Breast Cancer Portfolio
Pfizer Pflash: A Spotlight on Pfizer’s Breast Cancer Portfolio June 12, 2025 Classified – Confidential Presentation intended 1 for the investment community
Slide 2: Forward-Looking Statements and Other Notices
Our discussions during this presentation will include forward-looking prove inaccurate or incomplete, and are subject to risks, uncertainties statements about, among other topics, Pfizer Oncology, including and other factors that may cause actual results to differ materially from Forward-Looking Pfi
Slide 3: Today's Speakers
Today’s Speakers Hosted by Francesca Megan Johanna DeMartino O'Meara Bendell Chief Investor Head of Oncology Early Chief Development Officer Relations Officer Clinical Development Oncology 3
Slide 4: Pfizer Oncology Strategy
Pfizer Oncology Strategy Accelerate breakthroughs that help people with cancer live better and longer lives Modality Focus Therapeutic Area Focus Enabled by Deep Technical Expertise Building on Established Presence Unique ability to combine and adapt modalities to improve outcomes Deepen our ability
Slide 5: Breast Cancer is a Collection of Multiple Diseases
Breast Cancer is a Collection of Multiple Diseases Breast Cancer is Treated According to Stage and Subtype Early Breast Cancer Breast Cancer Subtype Distribution1 Has not spread beyond breast or axillary ~330K new diagnoses per year in U.S.2 lymph nodes Worsening Prognosis TNBC 10-15% Locally Advanc
Slide 6: Building on Breast Cancer Legacy Established with IBRANCE
Building on Breast Cancer Legacy Established with IBRANCE April 2025 Approval Expands IBRANCE Label INAVO120 February 3, 2025 Adding inavolisib to IBRANCE + fulvestrant improved overall survival in PIK3CA mutated, HR+ HER2-, endocrine-resistant locally advanced or metastatic breast cancer1 Recent Ph
Slide 7: Developing Therapies Across the Breast Cancer Spectrum
Developing Therapies Across the Breast Cancer Spectrum1 (Neo)adjuvant First-line Second-line3 Later Lines3 HR+ Atirmo KAT6i KAT6i Vepdeg2 HER2- Atirmo 65-70% CDK2i Vepdeg2 Vepdeg2 DV (HER2-low) HER2+ DV DV 15-20% Atirmo DV (HER2-low) TNBC 10-15% KAT6i Approved Registrational Program Ongoing or Plann
Slide 8: Atirmo is a Potential Best-in-Class, Highly Selective CDK4 Inhibitor
Atirmo is a Potential Best-in-Class, Highly Selective CDK4 Inhibitor Approved CDK4/6 inhibitors can lead to neutropenia largely due to contribution from CDK6 inhibition1 Rationale for Selectively Targeting CDK4 While Relative CDK4 vs. CDK6 Selectivity of Atirmo Sparing CDK6 and Approved CDK4/6 Inhib
Slide 9: Encouraging Ph 1/2 Data for Atirmo + Letrozole in 1L HR+ HER2- mBC
Encouraging Ph 1/2 Data for Atirmo + Letrozole in 1L HR+ HER2- mBC 20 Treatment Related AEs 0 Ph 1/2: Atirmo + Letrozole in 1L HR+ -20 HER2- Metastatic Breast Cancer (N=34)1 All Grades Grade 3/4 -40 Neutropenia 62% 24% Diarrhea 3% 0% -60 61% cORR1 Dose Reduction 9% due to TRAE -80 94% CBR1 ■ SD ■ PR
Slide 10: Developing Atirmo in First-line and Early HR+ HER2- Breast Cancer
Developing Atirmo in First-line and Early HR+ HER2- Breast Cancer Phase 3 Trial of Atirmo in First-line HR+ HER2- Breast Cancer Ongoing (FourLight-3) N≈1020 Key Inclusion Criteria • Locally advanced or Atirmo + Letrozole metastatic (a/m) disease • No prior systemic anti-cancer R Investigator’s Choic
Slide 11: KAT6i MOA is Potentially Well Suited for 2L+ HR+ HER2- Breast Cancer
KAT6i MOA is Potentially Well Suited for 2L+ HR+ HER2- Breast Cancer Proposed MOA: KAT6i Represses ER Transcription and Other Oncogenic Pathways1 Murine Xenograft IHC Data KAT6i binding inhibits Brown Staining = ER Expression2 1 histone acetylation KAT6A/B EAF6 Vehicle ING5 BRPF1 Reduced histone ace
Slide 12: Compelling Ph 1 Data for KAT6i in Post-CDK4/6i, 2L+ ER+ HER2- mBC
Compelling Ph 1 Data for KAT6i in Post-CDK4/6i, 2L+ ER+ HER2- mBC 5 mg QD KAT6i Identified as Deep and Durable Antitumor Activity with RP3D in Combination with 5 mg QD KAT6i + Fulvestrant1 Fulvestrant Tumor Size Change from Baseline Tolerable Safety Profile Acceptable PK Profile Strong Pharmacodynam
Slide 13: CDK2i is Designed to Delay or Overcome CDK4/6 Inhibitor Resistance
CDK2i is Designed to Delay or Overcome CDK4/6 Inhibitor Resistance CDK2 is Associated with Tumor CRISPR Screens Support Cyclin E/CDK2 Gene Expression Analyses from Growth and Activated by Cyclin E Complexes as Drivers of Resistance to CDK4/6 Phase 3 PALOMA-3 Trial Support Role and Cyclin A Inhibitio
Slide 14: Promising Early Antitumor Activity with Atirmociclib + CDK2i Combo
Promising Early Antitumor Activity with Atirmociclib + CDK2i Combo Phase 1b/2 Trial1: Heavily pretreated patients with HR+ HER2- mBC with measurable disease (n=182) 80 Prior CDK4/6 inhibitor: 100% 60 Objective response rate: 27.8% Disease control rate: 55.6% sum of diameters for target lesions Best
Slide 15: Vepdegestrant: First PROTAC Degrader to Show Clinical Benefit in Ph 3
Vepdegestrant*: First PROTAC Degrader to Show Clinical Benefit in Ph 3 VERITAC-2 trial in 2L+ ER+ HER2- breast cancer met primary endpoint in ESR1m patients but not in ITT population Vepdegestrant Significantly Improved PFS vs. No Significant Difference in PFS with Fulvestrant in ESR1m Population1 V
Slide 16: Developing TUKYSA as a Backbone TKI in HER2+ Breast Cancer
Developing TUKYSA as a Backbone TKI in HER2+ Breast Cancer Pivotal readout in first-line maintenance setting anticipated later this year Metastatic Breast Cancer Adjuvant Breast Cancer Approved PFS Reached Fully Enrolled Enrolling Phase 2 Phase 3 Phase 3 Phase 3 HER2CLIMB: HER2CLIMB-02: HER2CLIMB-05
Slide 17: Summary: Developing Therapies Across the Breast Cancer Spectrum
Summary: Developing Therapies Across the Breast Cancer Spectrum Building on leading legacy established with IBRANCE Multiple Potential Avenues to Address Unmet Patient Need and Drive Growth Expansion of Approved Products Atirmociclib in 1L & Early Breast Cancer Recent FDA approval of inavolisib comb
Slide 18: Potential Growth Catalysts in Breast Cancer Pipeline
Potential Growth Catalysts in Breast Cancer Pipeline Global Breast Cancer Market1 Early BC Metastatic BC ~9% CAGR ~$60B (2030) (Neo)adjuvant 1st Line 2nd Line 3rd Line ~$30B (2023) U.S. Epi: ~220k* U.S. Epi: ~35k* U.S. Epi: ~20k* U.S. Epi: ~10k* Atirmo Atirmo KAT6i KAT6i Subtype2 CDK2i DV (HER2-low)
Slide 19: Q&A Session
Q&A Session Moderated by Francesca Megan Johanna DeMartino O'Meara Bendell Chief Investor Head of Oncology Early Chief Development Officer Relations Officer Clinical Development Oncology 19